Last updated on July 2020

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Brief description of study

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.

Clinical Study Identifier: NCT03498521

Find a site near you

Start Over

Icon Cancer Foundation

South Brisbane, Australia
  Connect »

Flinders Medical Centre

Bedford Park, Australia
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Erasmus MC

Rotterdam, Netherlands
  Connect »

Blacktown Hospital

Blacktown, Australia
  Connect »

Velindre Cancer Centre

Cardiff, United Kingdom
  Connect »

Christie Hospital NHS Trust

Manchester, United Kingdom
  Connect »

Freeman Hospital

Newcastle upon Tyne, United Kingdom
  Connect »

Southampton General Hospital

Southampton, United Kingdom
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

CHRU Besan on

Besançon, France
  Connect »

Oncomedica S.A.

Monteria, Colombia
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.